We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.825
Bid: 0.80
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.05 (6.25%)
Open: 0.81
High: 0.85
Low: 0.80
Prev. Close: 0.825
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

Thu, 11th Feb 2021 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

MediaZest, more than trebled to 0.16 pence, 12-month range 0.0150p-0.1788p. The audio visual services firm has made a strong start to calendar year 2021, sealing new business wins. In total, new business wins will generate over GBP350,000 in revenue. The stock had closed at 0.050p on Wednesday.

----------

Clear Leisure, up 68% at 1.15 pence, 12-month range 0.110p-1.365p. The company seals GBP680,000 of extra cash through a placing of 113.3 million shares at 0.60 pence each. The technology sector-focused investor will use the funds for working capital and for "selective" further investments.

----------

N4 Pharma, up 14% at 9.24 pence, 12-month range 2.00p-16.00p. The Derbyshire-based pharmaceutical company reports the European Commission intends to grant a patent for Nuvec, a potential cancer treatment. N4 has "exclusive worldwide rights" for Nuvec.

----------

AIM - LOSERS

----------

Europa Oil & Gas, down 18% at 1.35p, 12-month range 0.550p-2.100p. The UK, Ireland and Morocco-focused oil and gas explorer plans to raise GBP2 million through a placing and broker option, priced at 1.3p per share, a 21% discount to its 1.65p closing price on Wednesday. Funds will go towards furthering its UK fields, the Inezgane licence in Morocco and "evaluating late-stage appraisal/development projects".

----------

Eden Research, down 7.8% at 13.77p, 12-month range 4.42p-17.00p. The plastic-free formulation technology company expects revenue for 2020 to come in at GBP1.6 million, a 20% fall, with its pretax loss stretching to GBP2.6 million from GBP1.4 million.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.